Abstracts tagged "Sjogren’s syndrome and interferons"

Abstract Number: 1073 • 2017 ACR/ARHP Annual Meeting
Aberrant Cell Signaling in Peripheral Blood Mononuclear Cells upon Interferon Alpha Stimulation in Patients with Primary Sjögren’s Syndrome Associates with Type I Interferon Signature
Richard Davies¹, Daniel Hammenfors^1,2, Brith Bergum¹, Petra Vogelsang¹, Sonia Gavasso³, Johan G. Brun^2,4, Roland Jonsson^5,6 and Silke Appel¹, ¹Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ²Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ³Department of Neurology, Haukeland University Hospital, Bergen, Norway, ⁴Department of Clinical Science, University of Bergen, Bergen, Norway, ⁵Broegelmann Research laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ⁶Department of Rheumatology, Haukeland University Hospital, Bergen, Bergen, Norway
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a complex heterogeneous systemic autoimmune disease. Biomarkers for patient stratification are scarce. Several single nucleotide polymorphisms within type I…
Abstract Number: 3034 • 2016 ACR/ARHP Annual Meeting
A Selective JAK1 Inhibitor, Filgotinib Suppresses Lymphocytic Infiltration in Salivary Gland of Non Obese Diabetic Mice Via Suppression of BAFF and Chemokine Production of Salivary Gland Epithelial Cells
Jennifer Lee¹, Seo Hwa Kim², Haneul Kim³, Seung-Ki Kwok⁴, Ji Hyeon Ju⁵ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of, ²Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, ⁴[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Interferon(IFN) signatures are upregulated in patients with primary Sjogren’s syndrome (pSS) and interferons are considered to play a pathogenic role in pSS. Therefore, Janus…
Abstract Number: 1054 • 2015 ACR/ARHP Annual Meeting
A Potential Role of Type III Interferon in the Glandular Involvement of Sjögren’s Syndrome
Tania Mora¹, Felipe Alonso Masso Rojas², Araceli Paez², Mariana Patlan³, Misael Gómez-Mondragón², Alberto Aranda-Frausto⁴, Maya Chacón Pérez⁵ and Luis M. Amezcua-Guerra^6,7, ¹Rheumatology, National Institute of Cardiology, Mexico City, Mexico, ²Department of Cell Physiology, National Institute of Cardiology, Mexico City, Mexico, ³Department of Immunology, National Institute of Cardiology, Mexico City, Mexico, ⁴Department of Pathology, National Institute of Cardiology, Mexico City, Mexico, ⁵National Institute of Cardiology, Mexico City, Mexico, ⁶Immunology, National Institute of Cardiology, Mexico City, Mexico, ⁷Mexican Accreditation Council of Rheumatology, A.C., Mexico City, Mexico
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoinmune disorder characterized by lymphocytic infiltration of salivary and lachrymal glands. Recently, it has been showed that plasmacytoid…
Abstract Number: 1047 • 2014 ACR/ARHP Annual Meeting
Type I and II Interferon Signatures in Sjogren’s Syndrome: Contributions in Distinct Clinical Phenotypes and Sjogren’s Related Lymphomagenesis
Adrianos Nezos¹, Fotini Gravani², Efstathia K. Kapsogeorgou³, Michael Voulgarelis⁴, Haralampos M. Moutsopoulos⁴, Mary K. Crow⁵ and Clio Mavragani⁶, ¹Department of Physiology, School of Medicine, University of Athens, Athens, Greece, ²Department of Rheumatology, General Hospital of Athens "G.Gennimatas", Athens, Greece, ³Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ⁴Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ⁵Department of Medicine, Hospital for Special Surgery, New York, NY, ⁶Department of Physiology, School of Medicine, University of Athens, Athens, Greece
Background/Purpose: Both type I and II interferons (IFNs) have been implicated in the pathogenesis of Sjogren’s syndrome (SS). We aimed to explore the contribution of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].